Abiraterone for prostate cancer not previously treated with hormone therapy
Authors
James, Nicholas D.de Bono, Johann S.
Spears, Melissa R.
Clarke, Noel W.
Mason, Malcolm D.
Dearnaley, David P.
Ritchie, Alastair W.S.
Amos, Claire L.
Gilson, Clare
Jones, Rob J.
Matheson, David
Millman, Robin
Attard, Gerhardt
Chowdhury, Simon
Cross, William R.
Gillessen, Silke
Parker, Christopher C.
Russell, J. Martin
Berthold, Dominik R.
Brawley, Chris
Adab, Fawzi
Aung, San
Birtle, Alison J.
Bowen, Jo
Brock, Susannah
Chakraborti, Prabir
Ferguson, Catherine
Gale, Joanna
Gray, Emma
Hingorani, Mohan
Hoskin, Peter J.
Lester, Jason F.
Malik, Zafar I.
McKinna, Fiona
McPhail, Neil
Money-Kyrle, Julian
O’Sullivan, Joe
Parikh, Omi
Protheroe, Andrew
Robinson, Angus
Srihari, Narayanan N.
Thomas, Carys
Wagstaff, John
Wylie, James
Zarkar, Anjali
Parmar, Mahesh K.B.
Sydes, Matthew R.
Issue Date
2017-06-03
Metadata
Show full item recordAbstract
BACKGROUND Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a multigroup, multistage trial design. METHODS We randomly assigned patients in a 1:1 ratio to receive ADT alone or ADT plus abiraterone acetate (1000 mg daily) and prednisolone (5 mg daily) (combination therapy). Local radiotherapy was mandated for patients with node-negative, nonmetastatic disease and encouraged for those with positive nodes. For patients with nonmetastatic disease with no radiotherapy planned and for patients with metastatic disease, treatment continued until radiologic, clinical, or prostate-specific antigen (PSA) progression; otherwise, treatment was to continue for 2 years or until any type of progression, whichever came first. The primary outcome measure was overall survival. The intermediate primary outcome was failure-free survival (treatment failure was defined as radiologic, clinical, or PSA progression or death from prostate cancer). RESULTS A total of 1917 patients underwent randomization from November 2011 through January 2014. The median age was 67 years, and the median PSA level was 53 ng per milliliter. A total of 52% of the patients had metastatic disease, 20% had node-positive or node-indeterminate nonmetastatic disease, and 28% had node-negative, nonmetastatic disease; 95% had newly diagnosed disease. The median follow-up was 40 months. There were 184 deaths in the combination group as compared with 262 in the ADT-alone group (hazard ratio, 0.63; 95% confidence interval [CI], 0.52 to 0.76; P<0.001); the hazard ratio was 0.75 in patients with nonmetastatic disease and 0.61 in those with metastatic disease. There were 248 treatment-failure events in the combination group as compared with 535 in the ADT-alone group (hazard ratio, 0.29; 95% CI, 0.25 to 0.34; P<0.001); the hazard ratio was 0.21 in patients with nonmetastatic disease and 0.31 in those with metastatic disease. Grade 3 to 5 adverse events occurred in 47% of the patients in the combination group (with nine grade 5 events) and in 33% of the patients in the ADT-alone group (with three grade 5 events). CONCLUSIONS Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure-free survival than ADT alone. (Funded by Cancer Research U.K. and others; STAMPEDE ClinicalTrials.gov number, NCT00268476, and Current Controlled Trials number, ISRCTN78818544.)Citation
James, N., de Bono, J., Spears, M., Clarke, N. W., Mason, M., Dearnaley, D., Ritchie, A., Amos, C., Gilson, C., Jones, R., Matheson, D. J., Millman, R., Attard, G., Chowdhury, S., Cross, W., Gillessen, S., Parker, C., Russell, M., Berthold, D., Brawley, C., Adab, F., Aung, S., Birtle, A. J., Bowen, J., Brock, S., Chakraborti, P., Ferguson, C., Gale, J., Gray, E, Hingorani, M., Hoskin, P., Lester, J., Malik, Z., McKinna, F., McPhail, N., Money-Kyrle, J., O'Sullivan, J., Parikh, O., Protheroe, A., Robinson, A.., Srihari, N., Thomas, C., Wagstaff, J., Wylie, J., Zarkar, A., Parmar, M. and Sydes, M. (2017) Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. The New England journal of medicine, 377 (4). pp. 338-351.Publisher
Massachusetts Medical SocietyJournal
New England Journal of MedicineAdditional Links
http://www.nejm.org/doi/10.1056/NEJMoa1702900Type
Journal articleLanguage
enDescription
© 2017 The Authors. Published by Massachusetts Medical Society. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1056/NEJMoa1702900ISSN
0028-4793Sponsors
The Medical Research Council sponsored the study and was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript. Funding was also provided by Cancer Research UK, Astellas, Janssen, Novartis, Sanofi-Aventis, and Pfizer, none of which were directly involved in the researchae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa1702900
Scopus Count
Collections
The following licence applies to the copyright and re-use of this item:
- Creative Commons
Except where otherwise noted, this item's license is described as https://creativecommons.org/CC BY-NC-ND 4.0